Clinical Problem
Chronic liver disease and IBD both suffer from systemic side effects, poor localized retention, relapse, inflammation, and the need for mucosal or organ-specific healing rather than broad exposure.
Localized Organ and Mucosal Delivery
Bioadhesive sprays and thermo-responsive hydrogels for liver fibrosis and inflammatory bowel disease.
This platform includes BioNano Spray for chronic liver disease and TofaMucoHeal/ColoRegen for localized JAK inhibitor delivery in IBD.
405nm
Light-triggered gelation
ICMR
Clinical-trial funding support
JAK
Localized IBD payload
Mechanism
BioNano Spray forms a thin hydrogel layer after 405 nm light exposure, while TofaMucoHeal uses a PNIPAM-HA thermo-responsive matrix to localize a JAK inhibitor at inflamed mucosa.
Material Platform
Hyaluronic acid, polydopamine, exosome nanotherapeutics, and thermo-responsive PNIPAM-HA copolymer matrices designed for controlled release and localized tissue interaction.
Proof & Translation
Resources describe significant liver regeneration in preclinical studies with improvements in histological and biochemical parameters plus modulation of gut microbiota and liver microvasculature.
How It Works
Simulation Linked01
Target
A laparoscopic spray or rectal formulation places therapy directly at the organ or mucosal surface.
02
Gel
The biomaterial transitions into a retained hydrogel layer through light or temperature response.
03
Release
Exosomes or JAK inhibitors are released locally to support regeneration and reduce systemic toxicity.
Why It Matters
- Localized therapy designed to minimize systemic side effects
- Sustained and controlled release of encapsulated bioactives
- Potential use across internal organs accessible by laparoscopy
- Mucosal healing focus for long-term remission in IBD
Translation Status
Current Status: Seeking regulatory approvals for clinical trials